(
Walter and Eliza Hall Institute) WEHI has partnered with Boehringer Ingelheim, a leading research-driven pharmaceutical company, in a collaboration to discover and develop anti-cancer therapeutics using a promising new technology called targeted protein degradation.The collaboration between WEHI and Boehringer Ingelheim will bring the two organizations' combined expertise in the biology and therapeutic targeting of IAPs, protein degradation and drug discovery to target cancer-causing proteins.
